Last reviewed · How we verify
225Ac-TR2205 Injection — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
225Ac-TR2205 Injection (225Ac-TR2205 Injection) — Xiaorong Sun.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| 225Ac-TR2205 Injection TARGET | 225Ac-TR2205 Injection | Xiaorong Sun | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- 225Ac-TR2205 Injection CI watch — RSS
- 225Ac-TR2205 Injection CI watch — Atom
- 225Ac-TR2205 Injection CI watch — JSON
- 225Ac-TR2205 Injection alone — RSS
Cite this brief
Drug Landscape (2026). 225Ac-TR2205 Injection — Competitive Intelligence Brief. https://druglandscape.com/ci/225ac-tr2205-injection. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing